Anti-rabies vaccines applied in the Russian Federation and perspectives for their improvement

Cover Page


Cite item

Full Text

Abstract

Rabies is almost ubiquitous (except in certain areas) and poses a significant danger to both animals and humans. Every year around 55,000 people die from this disease worldwide. In the Russian Federation alone 400,000– 

450,000 patients annually apply for anti-rabies treatment. In the absolute majority of cases human infection is caused by contact with infected animals. In RF, a number of cultured inactivated anti-rabies vaccines for medical and veterinary purposes have been developed, registered and used for specific prevention of rabies. These vaccine preparations have shown high effectiveness in preventing infection in domestic and farm animals. At the same time, the main reservoir of the rabies virus (Mononegavirales: Rhabdoviridae: Lyssavirus) (RV) are wild carnivores (Mammalia: Carnivora). For the purpose of their oral immunization, live virus vaccines from attenuated (fixed) strains of RV that are little resistant in the external environment are used. In Western Europe and North America there is successful experience with recombinant anti-rabies vaccine preparations containing a viral glycoprotein gene (G-protein). Such vaccines are safe for humans and animals. In Russia also had been developed a vector anti-rabies vaccine based on adenovirus (Adenoviridae), which can be used to combat this infection. Currently, in addition to classical rabies, diseases caused by new, previously unknown lyssaviruses (Lyssavirus) are becoming increasingly important. Bats (Mammalia: Microchiroptera) are their vectors. Cases of illness and death after contact with these animals have been described. In the near future, we should expect the development of new vaccines that will provide protection not only against RV, but also against other lyssaviruses.

About the authors

A. L. Elakov

FSBSI «Federal Scientific Center – All-Russian Scientific Research Institute of Experimental Veterinary Medicine named
after K.I. Skryabin and Ya.R. Kovalenko of the Russian Academy of Sciences»

Author for correspondence.
Email: alelakov@mail.ru
ORCID iD: 0000-0001-5798-6518

Alexandr L. Elakov (A. L. Elakov ), Ph.D., senior researcher at the Laboratory of Molecular diagnostics

109428, Moscow

Россия

References

  1. WHO Expert Consultation on Rabies: first report. In: WHO. Technical Report Series. Geneva; 2004: 931. Available at: https://apps.who.int/iris/bitstream/handle/10665/43262/WHO_TRS_931_eng.pdf?sequence=1&isAllowed=y (accessed January 18, 2022).
  2. Maier T., Schwarting A., Mauer D., Ross R.S., Martens A., Kliem V., et al. Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin. Infect. Dis. 2010; 50(8): 1112–9. https://doi.org/10.1086/651267
  3. Бардина Н.С., Титов М.А., Караулов А.К. Бешенство в России. Оценка риска. Информационно-аналитический обзор. Владимир; 2008.
  4. Зайкова О.Н., Гребенникова Т.В., Елаков А.Л., Кочергин-Никитский К.С., Алипер Т.И., Чучалин С.Ф., и др. Молекулярно-генетическая характеристика геномов полевых изолятов вируса бешенства, циркулирующих на территории Кировской области. Вопросы вирусологии. 2016; 61(4): 186–92. https://doi.org/10.18821/0507-4088-2016-61-4-186-192
  5. Зайкова О.Н., Гребенникова Т.В., Гулюкин А.М., Шабейкин А.А., Полякова И.В., Метлин А.Е. Молекулярно-генетическая характеристика полевых изолятов вируса бешенства, выявленных на территории Владимирской, Московской, Тверской, Нижегородской и Рязанской областей. Вопросы вирусологии. 2017; 62(3): 101–8. https://doi.org/10.18821/0507-4088-2017-62-3-101-108
  6. Мовсесянц А.А., Олефир Ю.В. Современные проблемы вакцинопрофилактики бешенства. БИОпрепараты. Профилактика, диагностика, лечение. 2019; 19(1): 10–6. https://doi.org/10.30895/2221-996X-2019-19-1-10-16
  7. Бутырский А.Ю., Мухачева А.В., Мовсесянц А.А., Саркисян К.А. Анализ результатов определения вируснейтрализующих антител в сыворотках крови лиц, привитых от бешенства. Вопросы вирусологии. 2019; 64(6): 298–305. https://doi.org/10.36233/0507-4088-2019-64-6-298-305
  8. Елаков А.Л. Антирабические вакцины для животных, применяемые в России. VetPharma. 2013; 4: 32–4.
  9. Елаков А.Л. Меры борьбы с бешенством у безнадзорных и диких животных. VetPharma. 2013; 5-6: 24–7.
  10. Елаков А.Л., Уласов В.И., Баньковский Д.О., Пестова Г.В., Маслов Е.В., Кожушко М.Ю., и др. Динамика снижения активности оральных антирабических вакцин при различных режимах хранения. В кн.: Материалы Международной научно-практической конференции «Задачи ветеринарной науки в реализации доктрины продовольственной безопасности Российской Федерации». Покров; 2011: 208–11.
  11. Грибенча С.В., Львов Д.К., Щелканов М.Ю. Рабдовирусы (Rhabdoviridae). В кн.: Львов Д.К., ред. Руководство по вирусологии. Вирусы и вирусные инфекции человека и животных. М.: МИА; 2013: 197–202.
  12. Lafon M., Ideler J., Wunner W. Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies. Dev. Biol. Stand. 1983; 57: 219–25.
  13. Dietzschold В., Wiktor T.J., Wunner W.H., Varrichio A. Chemical and immunological analysis of the rabies soluble glycoprotein. Virology. 1983; 124(2): 330–7. https://doi.org/10.1016/0042-6822(83)90349-5
  14. Mansfield K.L., Johnson N., Fooks A.R. Identification of a conserved linear epitope at the N terminus of the rabies virus glycoprotein. J. Gen. Virol. 2004; 85(Pt. 11): 3279–83. https://doi.org/10.1099/vir.0.80362-0
  15. Takayama-Ito M., Ito N., Yamada K., Minamoto N., Sugiyama M. Region at amino acids 164 to 303 of the rabies virus glycoprotein plays an important role in pathogenicity for adult mice. J. Neurovirol. 2004; 10(2): 131–5. https://doi.org/10.1080/13550280490279799
  16. Tuffereau C., Leblois H., Bénéjean J., Coulon P., Lafay F., Flamand A. Arginine or lysin in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virology. 1989; 172(1): 206–12. https://doi.org/10.1016/0042-6822(89)90122-0
  17. Dietzschold В., Wunner W., Wiktor Т., Lopes A.D., Lafon M., Smith C.L., et al. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl. Acad. Sci. USA. 1983; 80(1): 70–4. https://doi.org/10.1073/pnas.80.1.70
  18. Préhaud C., Lay S., Dietzschold B., Lafon M. Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis. J. Virology. 2003; 77(19): 10537–47. https://doi.org/10.1128/jvi.77.19.10537-10547.2003
  19. Tollis M., Dietzschold В., Viola C., Koprowski H. Immunization of monkeys of with rabies ribonucleoprotein (RNP) confers protective immunity against rabies. Vaccine. 1991; 9(2): 134–6. https://doi.org/10.1016/0264-410x(91)90270-g
  20. Wiktor T.J., Macfarlan R.I., Reagan K.J., Dietzschold B., Curtis P.J., Wunner W.H., et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. USA. 1984; 81(22): 7194–8. https://doi.org/10.1073/pnas.81.22.7194
  21. Rupprecht C.E., Wiktor T.J., Johnston D.H., Hamir A.N., Dietzschold B., Wunner W.H., et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc. Natl. Acad. Sci. USA. 1986; 83(20): 7947–50. https://doi.org/10.1073/pnas.83.20.7947
  22. Blancou J., Kieny M.P., Lathe R., Lecocq J.P., Pastoret P.P., Soulebot J.P., et al. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature. 1986; 322(6077): 373–5. https://doi.org/10.1038/322373a0
  23. Brochier В., Kieny M.P., Costy F., Coppens P., Bauduin В., Lecocq J.P., et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature. 1991; 354(6354): 520–2. https://doi.org/10.1038/354520a0
  24. Cliquet F., Barrat J., Guiot A.L., Cael N., Boutrand S., Maki J., et al. Efficacy and bait acceptance of vaccinia vectored rabies glycoprotein vaccine in captive foxes (Vulpes vulpes), raccoon dogs (Nyctereutes procyonoides) and dogs (Canis familiaris). Vaccine. 2008; 26(36): 4627–38. https://doi.org/10.1016/j.vaccine.2008.06.089
  25. Rupprecht C.E., Blass L., Smith K., Orciari L.A., Niezgoda M., Whitfield S.G., et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N. Engl. J. Med. 2001; 345(8): 582–6. https://doi.org/10.1056/nejmoa010560
  26. Rupprecht C.E., Hanlon C.A., Blanton J., Manangan J., Morrill P., Murphy S., et al. Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res. 2005; 111(1): 101–5. https://doi.org/10.1016/j.virusres.2005.03.017
  27. Amann R., Rohde J., Wulle U., Conlee D., Raue R., Martinon O., et al. A new rabies vaccine based on a recombinant ORF virus (Parapoxvirus) expressing the rabies virus glycoprotein. J. Virol. 2013; 87(3): 1618–30. https://doi.org/10.1128/JVI.02470-12
  28. Ge J., Wang X., Tao L., Wen Z., Feng N., Yang S., et al. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J. Virol. 2011; 85(16): 8241–52. https://doi.org/10.1128/jvi.00519-11
  29. Saxena S., Dahiya S.S., Sonwane A.A., Patel C.L., Saini M., Rai A., et al. A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge. Vaccine. 2008; 26(51): 6592–601. https://doi.org/10.1016/j.vaccine.2008.09.055
  30. Yuan Z., Zhang S., Liu Y., Zhang F., Fooks A.R., Li Q., et al. A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs. Vaccine. 2008; 26(10): 1314–21. https://doi.org/10.1016/j.vaccine.2007.12.050
  31. Prehaud C., Takehara K., Flamand A., Bishop D.H. Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors. Virology. 1989; 173(2): 390–9. https://doi.org/10.1016/0042-6822(89)90551-5
  32. Poulet H., Minke J., Pardo M.C., Juillard V., Nordgren B., Audonnet J.C. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine. 2007; 25(30): 5606–12. https://doi.org/10.1016/j.vaccine.2006.11.066
  33. Chen Z., Zhou M., Gao X., Zhang G., Ren G., Gnanadurai C.W., et al. A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein. J. Virol. 2013; 87(6): 2986–93. https://doi.org/10.1128/JVI.02886-12
  34. Yarosh O.K., Wandeler A.I., Graham F.L., Campbell J.B., Prevec L. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine. 1996; 14(13): 1257–64. https://doi.org/10.1016/s0264-410x(96)00012-6
  35. Tims T., Briggs D.J., Davis R.D., Moore S.M., Xiang Z., Ertl H.C., et al. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine. 2000; 18(25): 2804–7. https://doi.org/10.1016/s0264-410x(00)00088-8
  36. Шмаров М.М., Седова Е.С., Никонова А.Э., Елаков А.Л., Щербинин Д.Н., Артемова Э.А., и др. Иммуногенные и защитные свойства рекомбинантного аденовируса человека 5-го серотипа, экспрессирующего ген гликопротеина G вируса бешенства вакцинного штамма РВ-97. Иммунология. 2020; 41(4): 312–25. https://doi.org/10.33029/0206-4952-2020-41-4-312-325
  37. Груздев К.Н., Недосеков В.В. Бешенство животных. М.: Аквариум; 2001.
  38. Banyard A.C., Evans J.S., Luo T.R., Fooks A.R. Lyssaviruses and bats: emergence and zoonotic threat. Viruses. 2014; 6(8): 2974–90. https://doi.org/10.3390/v6082974
  39. Walker P.J., Blasdell K.R., Calisher C.H., Dietzgen R.G., Kondo H., Kurath G., et al. ICTV virus taxonomy profile: Rhabdoviridae. J. Gen. Virol. 2018; 99(4): 447–8. https://doi.org/10.1099/jgv.0.001020
  40. Aréchiga Ceballos N., Vázquez Morón S., Berciano J.M., Nicolás O., Aznar López C., Juste J., et al. Novel lyssavirus in bat, Spain. Emerg. Infect. Dis. 2013; 19(5): 793–5. https://doi.org/10.3201/eid1905.121071
  41. Gunawardena P.S., Marston D.A., Ellis R.J., Wise E.L., Karawita A.C., Breed A.C., et al. Lyssavirus in Indian flying foxes, Sri Lanka. Emerg. Infect. Dis. 2016; 22(8): 1456–9. https://doi.org/10.3201/eid2208.151986
  42. Hu S.C., Hsu C.L., Lee M.S., Tu Y.C., Chang J.C., Wu C.H., et al. Lyssavirus in Japanese Pipistrelle, Taiwan. Emerg. Infect. Dis. 2018; 24(4): 782–5. https://doi.org/10.3201/eid2404.171696
  43. Badrane H., Bahloul C., Perrin P., Tordo N. Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J. Virol. 2001; 75(7): 3268–76. https://doi.org/10.1128/jvi.75.7.3268-3276.2001
  44. Fooks A.R., Banyard A.C., Horton D.L., Johnson N., McElhinney L.M., Jackson A.C. Current status of rabies and prospects for elimination. Lancet. 2014; 384(9951): 1389–99. https://doi.org/10.1016/s0140-6736(13)62707-5
  45. Malerczyk C., Freuling C., Gniel D., Giesen A., Selhorst T., Müller T. Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species. Hum. Vaccin. Immunother. 2014; 10(10): 2799– 804. https://doi.org/10.4161/21645515.2014.972741
  46. Dacheux L., Larrous F., Mailles A., Boisseleau D., Delmas O., Biron C., et al. European bat Lyssavirus transmission among cats, Europe. Emerg. Infect. Dis. 2009; 15(2): 280–4. https://doi.org/10.3201/eid1502.080637
  47. Nokireki T., Jakava-Viljanen M., Virtala A.M., Sihvonen L. Efficacy of rabies vaccines in dogs and cats and protection in a mouse model against European bat lyssavirus type 2. Acta Vet. Scand. 2017; 59(1): 64. https://doi.org/10.1186/s13028-017-0332-x
  48. Ботвинкин А.Д. Вирусы и летучие мыши: междисциплинарные проблемы. Вопросы вирусологии. 2021; 66(4): 259–68. https://doi.org/10.36233/0507-4088-79

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Elakov A.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies